Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AbbVie Meets Primary Endpoint | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances, Trials & Filings

AbbVie Meets Primary Endpoint

In cooperation with Neurocrine Biosciences for the treatment of uterine fibroids

By: Betsy Louda

, Contract Pharma

AbbVie, in cooperation with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met its primary endpoint. 

 

Results from the first of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone (add-back) therapy, reduced heavy menstrual bleeding with 68.5 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (8.7 percent), as measured by the alkaline hematin method. The study also met all ranked secondary endpoints (p<0.001) at month six.

 

Uterine fibroids are the most common type of abnormal growth in a woman’s pelvis and can affect up to 80 percent of women by age 50.

 

“Current non-surgical treatments are limited and women suffering from uterine fibroids need more therapeutic options,” said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. “The results from this study represent a significant advancement in the development of elagolix and demonstrate our continued commitment to address serious disease.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics